Emmerich J, Aubert I, Bauduceau B, Dachet C, Chanu B, Erlich D, Gautier D, Jacotot B, Rouffy J
Unité de recherches sur les dyslipidémies et l'athérosclérose, INSERM U 32, Hôpital Henri Mondor, Creteil, France.
Eur Heart J. 1990 Feb;11(2):149-55. doi: 10.1093/oxfordjournals.eurheartj.a059671.
The effects and safety of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, were investigated alone or in association with cholestyramine in 66 patients with hypercholesterolaemia, in a 1-year study. In type IIa hypercholesterolaemia (41 patients), the association was more effective than simvastatin used alone in lowering total cholesterol (37% vs 29%) and LDL-cholesterol (45% vs 37%). In type IIb hypercholesterolaemia (23 patients), the association simvastatin-cholestyramine did not appear more effective than simvastatin used alone. The decrease of apoprotein B was parallel to the LDL-cholesterol decrease. Apoprotein A1 did not change significantly. The long-term safety of simvastatin was good. No lens opacity was noted. The most serious side-effect in our study was myolysis which occurred in two patients with a marked increase in creatine phosphokinase.
